(9CI)-4,5,6,7-四氢-5-甲基-噻唑并[4,5-c]吡啶-2-胺 | 784079-98-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: (9CI)-4,5,6,7-四氢-5-甲基-噻唑并[4,5-c]吡啶-2-胺
• 英文名称: 5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2-amine
• 英文别名: 5-Methyl-4,5,6,7-tetrahydrothiazolo[4,5-c]pyridin-2-amine；5-methyl-6,7-dihydro-4H-[1,3]thiazolo[4,5-c]pyridin-2-amine
• CAS: 784079-98-7
• 化学式: C₇H₁₁N₃S
• mdl: MFCD11501141
• 分子量: 169.25
• InChiKey: ZYQDLARJCNEQHY-UHFFFAOYSA-N

物化性质

• 沸点：
  315.5±32.0 °C(Predicted)
• 密度：
  1.279±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (R)-4-(3-(1-(tert-butoxycarbonyl)piperidin-3-ylamino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)benzoic acid 、 (9CI)-4,5,6,7-四氢-5-甲基-噻唑并[4,5-c]吡啶-2-胺 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 1.5h， 以46%的产率得到tert-butyl (3R)-3-({1-[(4-methoxyphenyl)methyl]-4-[4-({5-methyl-4H,5H,6H,7H-[1,3]thiazolo[5,4-c]pyridin-2-yl}carbamoyl)phenoxy]-1H-pyrazolo[3,4-b]pyridin-3-yl}amino)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE
  [FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON

  摘要：

  本文披露了抑制布鲁顿酪氨酸激酶（Btk）的化合物。还描述了Btk的不可逆抑制剂。此外，还描述了Btk的可逆抑制剂。还披露了包括这些化合物的药物组合物。披露了使用Btk抑制剂的方法，单独或与其他治疗剂联合治疗自身免疫疾病或症状、异源免疫疾病或症状、癌症（包括淋巴瘤）和炎症性疾病或症状。

  公开号：

  WO2016004272A1

文献信息

• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：CHEN Wei

  公开号：US20160002225A1

  公开（公告）日：2016-01-07

  Disclosed herein are compounds that inhibit Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

  本文披露了能够抑制布鲁顿酪氨酸激酶（Btk）的化合物。同时还描述了Btk的不可逆抑制剂。此外，还描述了可逆的Btk抑制剂。还披露了包括这些化合物的药物组合物。本文还披露了使用Btk抑制剂的方法，单独或与其他治疗药物联合使用，用于治疗自身免疫性疾病或情况，异体免疫性疾病或情况，癌症，包括淋巴瘤，以及炎症性疾病或情况。
• NOVEL THIAZOLE DERIVATIVE
  申请人：YAMANOUCHI PHARMACEUTICAL CO. LTD.

  公开号：EP0555480A1

  公开（公告）日：1993-08-18

  A novel thiazole derivative represented by general formula (I), which has a selective agonistic activity for 5-HT₃ receptor, a pharmaceutical composition thereof, and a process for producing the same. In the said formula, R¹ represents hydrogen or lower alkoxy; R² and R³ are such that R² represents hydrogen and R³ represents a group, -Y-Het, wherein Y represents a single bond or lower alkylene and Het represents a nitrogenous heterocyclic group, or alternatively R² and R³ are combined together to form a group, -(CH₂)m-NR⁴-(CH₂)n-, wherein m and n are each 1 or 2 and R⁴ represents lower alkyl; and X represents -NH-, -NHC(=O)NH-, -C(=O)NH- or -NHC(=O)-.

  一种由通式(I)表示的新型噻唑衍生物，它对 5-HT₃ 受体具有选择性激动活性；一种其药物组合物；以及生产该衍生物的工艺。在上述通式中，R¹代表氢或低级烷氧基；R²和R³是这样的：R²代表氢，R³代表基团-Y-Het，其中Y代表单键或低级亚烷基，Het代表含氮杂环基团，或者R²和R³组合在一起形成基团-(CH₂)m-NR⁴-(CH₂)n-，其中m和n各自为1或2，R⁴代表低级烷基；X 代表-NH-、-NHC(＝O)NH-、-C(＝O)NH- 或-NHC(＝O)-。
• Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
  申请人：LegoChem Biosciences, Inc.

  公开号：US10961242B2

  公开（公告）日：2021-03-30

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.

  本发明涉及作为自体毒素抑制剂的新型化合物，用于治疗和预防由自体毒素激活或溶血磷脂酸浓度升高引起的病症或紊乱，以及含有本发明的药物组合物。 本发明的新型化合物是自体毒素抑制剂，通过抑制溶血磷脂酸的产生，可用于治疗或预防心血管疾病、癌症、代谢紊乱、肾脏疾病、肝脏疾病、炎症性疾病、神经系统疾病、呼吸系统疾病、纤维化疾病、眼部疾病、胆汁淤积性和其他形式的慢性瘙痒症，或急性或慢性器官移植排斥反应。
• NOVEL COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
  申请人：LegoChem Biosciences, Inc.

  公开号：US20200172542A1

  公开（公告）日：2020-06-04

  The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.
• US9580416B2
  申请人：——

  公开号：US9580416B2

  公开（公告）日：2017-02-28